The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal–fetal transmission: a systematic review and meta-analysis

Kuma Diriba* , Ephrem Awulachew and Eyob Getu

Abstract

Background: Coronavirus is challenging the global health care system from time to time. The pregnant state, with alterations in hormone levels and decreased lung volumes due to a gravid uterus and slightly immunocompromised state may predispose patients to a more rapidly deteriorating clinical course and can get a greater risk of harm for both the mother and fetus. Therefore, this systematic review was aimed to assess the effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and its possibility of vertical maternal–fetal transmission.

Methods: A systematic search was conducted on PubMed, Web of Science, Embase, Google Scholar and the Cochrane Library until the end of April. All authors independently extracted all necessary data using excel spreadsheet form. Only published articles with fully accessible data on pregnant women infected with SARS-CoV, MARS-CoV, and SARS-CoV-2 were included. Data on clinical manifestations, maternal and perinatal outcomes were extracted and analyzed.

Result: Out of 879 articles reviewed, 39 studies involving 1316 pregnant women were included. The most common clinical features were fever, cough, and myalgia with prevalence ranging from 30 to 97%, while lymphocytopenia and C-reactive protein were the most common abnormal laboratory findings (55–100%). Pneumonia was the most diagnosed clinical symptom of COVID-19 and non-COVID-19 infection with prevalence ranged from 71 to 89%. Bilateral pneumonia (57.9%) and ground-glass opacity (65.8%) were the most common CT imaging reported. The most common treatment options used were hydroxychloroquine (79.7%), ribavirin (65.2%), and oxygen therapy (78.8%). Regarding maternal outcome, the rate of preterm birth < 37 weeks of gestation was 14.3%, preeclampsia (5.9%), miscarriage (14.5%), preterm premature rupture of membranes (9.2%) and fetal growth restriction (2.8%). From the total coronavirus infected pregnant women, 56.9% delivered by cesarean, 31.3% admitted to ICU, while 2.7% were died. Among the perinatal outcomes, fetal distress rated (26.5%), neonatal asphyxia rated (1.4%). Only, 1.2% of neonates had apgar score < 7 at 5 min. Neonate admitted to ICU was rated 11.3%, while the rate of perinatal death was 2.2%. In the current review, none of the studies reported transmission of CoV from the mother to the fetus in utero during the study period.

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Coronaviruses (CoVs) are one of the major pathogens that are grouped in the family of Coronaviridae, which primarily target the human respiratory system [1]. It is one of the emerging and reemerging viral outbreaks throughout the world. Previous outbreaks of coronaviruses include the severe acute respiratory syndrome (SARS)-CoV epidemic in 2003 [2] and the Middle East respiratory syndrome (MERS)-CoV in 2012 [3], while the newly emergent coronavirus, initially referred to as 2019-nCoV and subsequently termed SARS-CoV-2, the disease it produces has been termed COVID-19, which causes respiratory infection and can progress to severe pneumonia and, in a small number of cases, death [4]. Although these coronaviruses were isolated from different human and animal hosts at different times and locations, they all belong to the species severe acute respiratory syndrome-related coronavirus [5, 6].

The increasing mortality rate warrants that vulnerable populations in the society be identified and protected. When COVID-19 and other CoV infect women who are pregnant, it increases the risk of adverse obstetrical and neonatal outcomes and results in severe respiratory disease [5]. Previous data from multiple studies of influenza and other respiratory infectious diseases have demonstrated an increased risk of maternal obstetrical complications when compared with nonpregnant women due to physiological changes occurring during pregnancy [7]. This association has also been previously demonstrated to occur when pregnant women became infected with either of the two pathogenic coronavirus infections (SARS-CoV 2 and MERS-CoV) [8].

Coronavirus infection in pregnant women makes clinical management more difficult by prolonging and complicating the illness and compromises the treatment [9]. Researchers are still in question regarding the transmission of the novel and previous coronavirus infection from a pregnant woman to her fetus, a process termed vertical transmission [10–12]. There are few published cases of coronavirus disease occurring during pregnancy and due to the possibility of mother–fetal vertical transmission, there is a concern that the fetuses may be at risk of congenital COVID-19 and other CoV outbreaks. Due to the alarming spread of CoV outbreaks throughout the world, a comprehensive understanding of the transmission of the virus from mother to fetus in utero like other emerging viral infections as Zika virus and Ebola virus [13, 14], that can threaten the health and survival of an infected mother and fetus is essential for effective management of the infection and treatment. Therefore, this systematic review and meta-analysis was aimed to assess the effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and its possibility of vertical maternal–fetal transmission.

Methods
Study design
A systematic review and meta-analysis was aimed to assess the effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and its possibility of vertical maternal–fetal transmission following the methodological framework suggested by Arksey and O'Malley [15].

Search strategies
All relevant articles were searched without date limits using the following databases: PubMed, Web science, Embase, Google Scholar, Cochrane library, and Science Direct according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) [16]. All searches were limited to article written in English given that such language restriction does not alter the outcome of the systematic reviews and meta-analysis [17]. The gray literature of observational studies was searched through the review of reference lists and input of content experts. We searched scientific publications from 2003 to 2020. All papers published until the end of April 30, 2020, and fulfill the inclusion criteria were considered. The search used the following keywords: coronavirus, novel coronavirus-2019 infection, pregnancy, Middle East respiratory syndrome, severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus-2, and vertical transmission. We searched all terms with the help of Boolean operators like “AND” or “OR”.

Conclusion: Coronavirus infection is more likely to affect pregnant women. Respiratory infectious diseases have demonstrated an increased risk of adverse maternal obstetrical complications than the general population due to physiological changes occurred during pregnancy. None of the studies reported transmission of CoV from the mother to the fetus in utero, which may be due to a very low expression of angiotensin-converting enzyme-2 in early maternal–fetal interface cells.

Keywords: Coronavirus, Novel coronavirus-2019, Infection, Pregnancy, Vertical transmission, Middle East respiratory syndrome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus-2
Eligibility criteria
All articles with a report of pregnant women with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome coronavirus (SARS-CoV) and other related illness with different clinical features published in English from 2003 to April 30/2020 were included in the study. Case studies and case series reported pregnant women with confirmed coronavirus; other clinical features were included with caution. Studies pertaining to other coronavirus-related illnesses, studies that were not fully accessible, and duplicate publications of the same study were excluded.

Assessment of study quality
Studies selected for inclusion were assessed for methodological quality by all authors independently using the standard critical appraisal instruments of the Joanna Briggs Institute Meta-Analysis of Statistics Assessment Review Instrument (JBI-MAStARI) [18]. The disagreements were resolved by consensus.

Outcome measures
The primary outcome variable of this study was the pregnancy outcomes observed, listed as follows: preterm birth (PTB; either before 37 or 34 weeks of gestation), preeclampsia, preterm prelabor rupture of membranes. (pPROM), fetal growth restriction (FGR), miscarriage, maternal death, mode of delivery and other clinical feature, laboratory findings and coexisting disease. The secondary outcomes were the perinatal outcomes observed as listed: fetal distress, apgar score < 7 at 5 min, neonatal asphyxia, admission to the neonatal intensive care unit (NICU), perinatal death, including both stillbirth, and neonatal death, evidence of in utero transmission.

Data extraction and synthesis
The data were extracted using a standardized data extraction format, adapted from the Joanna Briggs Institute (JBI), by three authors (KD, EA, and AG), independently extracting all necessary data using an excel spreadsheet form. Then the extracted data were merged for systematic analysis. Any disagreements during the data extraction were resolved through discussion and consensus. The main outcomes extracted from the study were: primary author, study design, publication year, country, patient demographics, maternal and perinatal outcome, and evidence of in utero transmission of coronavirus. All clinical characteristics of pregnant women infected with coronavirus, laboratory and radiological findings, treatment options, and data on associated risk factors were extracted by the authors.

Statistical analysis
Following data extraction, systematic review and meta-analysis were conducted using R software version 3.6.1 and STATA statistical software (version 13) with user-contributed commands for meta-analyses: metaprop, metainf, metabias, and metareg [19]. The effect sizes and SEs of the studies were pooled using a random-effects model to calculate the pooled estimates of laboratory findings, other clinical features and coexisting diseases among patients with COVID-19 infection. A meta-analysis was also planned to assess the association of various comorbidities and laboratory findings with the severity of disease.

Risk of bias and sensitivity analysis
The standard error for each original study was calculated using the binomial distribution formula. Evidence for statistical heterogeneity among reported prevalence was assessed using the Cochrane Q-test and I² statistics [20]. The pooled proportion was estimated by using the back-transform of the weighted mean of the transformed proportions for both the fixed-effects model and the random-effects model [21]. A significance level of P<0.10 and I² > 50% was interpreted as evidence of heterogeneity [22, 23]. A potential source of heterogeneity was investigated by subgroup analysis and meta-regression analysis [24]. Where statistical pooling was not possible, the findings were presented in a narrative form including tables and figures to aid in data presentation where appropriate.

Sensitivity analyses were conducted to weigh up the relative influence of each individual study on the pooled effect size using a user-written function, metainf. The presence of publication bias was assessed informally by visual inspection of funnel plots [25]. Point prevalence, as well as 95% confidence intervals, was presented in the forest plot format.

Results
Study selection
Database searches identified a total of 879 articles. From these initial articles, 29 articles were excluded due to duplication. From the remaining 850 articles, 786 articles were excluded after review of their titles and abstracts confirmed nonrelevance to this review. Therefore, 64 full-text articles were assessed for eligibility based on the preset criteria, which resulted in the further exclusion of 25 articles primarily due to the outcome of the interest being not reported in the study. Ultimately, 39 studies met the eligibility criteria and were included in the final review (Fig. 1 and Table 1).
Description of included studies
In the current review, 39 articles with a total of 1316 pregnant women with laboratory-confirmed CoV [12, 26–49] infection [1271 with SARS-CoV-2 [12, 26–49], 12 with MERS-CoV [50–56] and 33 with SARS-CoV [57–63] (Table 1)] and reported different maternal and perinatal outcome were included in this study. Most of the studies included in this review were retrospective studies and case series as listed in Table 1. The number of pregnant women confirmed to be infected with SARS-CoV-2, MERS-CoV, and SARS-CoV in different studies ranged from 1 to 427. Majority of the studies that fulfill the inclusion criteria were from China (Table 1). The mean age of the study participants was 33.2 years with a standard deviation of 8.3 years. Out of the 39 studies, 30 papers reported severe disease among pregnant women with a prevalence of SARS-CoV-2 [20.1% (167/833)], MERS-CoV [66.7% (8/12)] and SARS-CoV [48.5% (16/33)] (Table 1).

Commonly reported clinical feature and laboratory finding of pregnant women infected with coronaviruses (SARS-CoV-2, MERS-CoV, and SARS-CoV)
From the total of 39 included studies, only 32 studies with a total of 914 pregnant women infected with coronavirus had reported different clinical features. Meta-analysis was performed for those different clinical features of pregnant women infected with coronavirus with available data. According to the report of 39 studies, fever, cough, and fatigue were the most common clinical features of coronavirus-infected pregnant women with prevalence ranged from 30 to 67% in SARS-CoV-2, 50–78% in MERS-CoV and 80–97% in SARS-CoV. The pooled prevalence of all clinical symptoms was 26% with 95% CI (15.2–40.1). Pneumonia was the most diagnosed clinical symptom among pregnant women in the three coronavirus infections with a prevalence of 71.2% in SARS-CoV-2, 71.4% in MERS-CoV and 88.9% in SARS-CoV (Table 2). Among the most
commonly reported laboratory findings, lymphocytopenia was the most frequently reported in the three coronavirus infections with prevalence ranged from 63 to 100%, followed by elevated C-reactive protein and leukopenia with prevalence ranged from 45 to 100% (Table 2).
Table 2 Pooled prevalence of clinical features and laboratory findings of pregnant women with coronavirus infection in the present systematic review and meta-analysis

| Clinical feature of patients with CoV infection | SARS-CoV-2 | MERS-CoV | SARS-CoV |
|-----------------------------------------------|------------|----------|----------|
| Study (n) | Reports (n) | Pregnancies (n) | Pooled % (95%-CI) | Study (n) | Reports (n) | Pregnancies (n) | Pooled % (95%-CI) | Study (n) | Reports (n) | Pregnancies (n) | Pooled % (95%-CI) |
| Fever | 19 | 575 | 870 | 66.1% [56.1–79.8] | 6 | 9 | 12 | 75% [30.2–88.9] | 7 | 32 | 33 | 96.9% [84.6–100] |
| Cough | 18 | 458 | 869 | 52.7% [34.7–67.7] | 4 | 7 | 9 | 77.8% [40.1–97.5] | 6 | 21 | 26 | 80.8% [61.4–93.6] |
| Fatigue | 8 | 192 | 634 | 30.3% [14.4–49.6] | 1 | 1 | 2 | 50% [1.2–99.2] | – | – | – | – |
| Dyspnea | 7 | 49 | 303 | 16.2% [7.6–223] | 1 | 1 | 2 | 50% [1.4–99.6] | 1 | 9 | 10 | 90% [55.3–100] |
| Myalgia | 5 | 61 | 293 | 20.8% [7.5–27.8] | 2 | 3 | 8 | 37.5 [9.3–76.2] | 2 | 16 | 22 | 72.7% [50.1–89.8] |
| Shortness of Breath | 6 | 186 | 586 | 31.7% [18.2–41.5] | 1 | 1 | 2 | 50% [1.4–99.6] | 3 | 9 | 24 | 37.5% [19.2–59.6] |
| Sore throat | 6 | 78 | 668 | 11.7% [5.1–29.1] | – | – | – | – | 2 | 5 | 22 | 22.7% [8.7–45.5] |
| Chill | 3 | 44 | 480 | 9.2% [4.7–71.1] | – | – | – | – | 3 | 15 | 23 | 65.2% [43.1–84.8] |
| Headache | 5 | 88 | 674 | 13.1% [8.5–33.2] | 1 | 1 | 2 | 50% [1.4–99.6] | 4 | 15 | 24 | 62.5% [41.3–81.9] |
| Muscle pain | 3 | 67 | 628 | 10.7% [4.9–25.4] | – | – | – | – | 2 | 2 | 11 | 18.2% [3.2–35.9] |
| Diarrhea | 9 | 41 | 753 | 5.4% [2.2–10.3] | 1 | 1 | 2 | 50% [1.4–99.6] | 2 | 3 | 22 | 13.6% [6.6–48.7] |
| Abdominal pain | 2 | 5 | 64 | 7.8% [3.5–17.1] | 1 | 1 | 2 | 50% [1.4–99.6] | – | – | – | – |
| Pneumonia | 21 | 368 | 517 | 71.2% [68.6–95.8] | 4 | 5 | 7 | 71.4% [29.5–96.2] | 5 | 8 | 9 | 88.9% [52.1–100] |
| Laboratory finding | | | | | | | | | | | | |
| Leukocytosis | 6 | 27 | 95 | 28.4% [20.1–39.6] | – | – | – | – | 3 | 10 | 24 | 41.7% [22.1–63.2] |
| Leukopenia | 6 | 43 | 95 | 45.3% [35.4–56.3] | – | – | – | – | 3 | 14 | 24 | 58.3% [37.2–78.3] |
| Lymphocytosis | 12 | 8 | 70 | 11.4% [5.5–21.3] | – | – | – | – | 4 | 3 | 24 | 125% [3.2–32.8] |
| Lymphocytopenia | 13 | 92 | 146 | 63% [55.7–71.4] | 1 | 1 | 1 | 100% [3.3–100] | 4 | 20 | 24 | 83.3% [63.1–95.5] |
| ALT† | 3 | 9 | 48 | 18.8% [9.5–33.7] | 2 | 1 | 3 | 33.3% [1.6–91.3] | 2 | 2 | 8 | 25% [3.3–65.3] |
| AST† | 3 | 8 | 48 | 16.7% [7.2–30.5] | 2 | 1 | 3 | 33.3% [1.6–91.3] | 2 | 2 | 8 | 25% [3.3–65.3] |
| LDH† | 3 | 8 | 23 | 34.8% [16.2–57.9] | – | – | – | – | – | – | – | – |
| C-reactive protein † | 11 | 80 | 143 | 55.9% [47.4–64.2] | 1 | 1 | 1 | 100% [3.3–100] | 1 | 1 | 1 | 100% [3.3–100] |

AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase

*Diriba et al. Eur J Med Res (2020) 25:39*
pneumonia with a prevalence of 65.8% and 57.9%, respectively (Table 3). In this study, ribavirin and oseltamivir were the most commonly used antiviral therapy used for the treatment of viral pathogens among pregnant women infected with coronaviruses with a prevalence of 65.2% and 56.5%, while the most common antibiotic therapy used for the treatment of common bacterial co-infection was azithromycin with prevalence of 35%. In this study, hydroxychloroquine was the leading drug used by people infected with coronaviruses with a prevalence of 79.7%. From the total coronavirus-infected pregnant women, around 78.8% were treated with oxygen therapy while 18.1% were supported by mechanical ventilation (Table 3).

The outcome of pregnant women infected with coronavirus and their newborn

Out of 1316 pregnant women infected with CoV, 46.5% give birth at >37 weeks of gestation, while the rates of PTB <34 and <37 weeks of gestation were 9.5% and 14.3%, respectively. Preeclampsia was reported among 5.9% of pregnant women, while the rate of miscarriage for CoV infection was 14.5%. pPROM and FGR were rated 9.2% and 2.8%, respectively. From the total CoV-infected pregnant women, 31.3% were admitted to ICU from which 2.7% were died. The prevalence of cesarean delivery was 56.9%, while 28.6% had undergone normal delivery. Fetal distress was reported in 26.5%, while neonatal asphyxia was reported in only 1.4% of neonates. Only, 1.2% of neonates had apgar score <7 at 5 min. Neonate admitted to ICU was rated 11.3%, while the rate of perinatal death was 2.2%. In the current review, none of the studies reported transmission of CoV from the mother to the fetus in utero during the follow-up period (Table 4).

In our systematic review, different comorbidities that aggravate the infection were found among pregnant women infected with CoV. From the total CoV-infected pregnant women, the rate of gestational diabetes was 9.6%, while hypertension was reported in 8.5% of pregnant women infected with CoV. The rate of asthma in pregnant women infected with CoV was 5.5%, while cardiovascular disease and digestive disease rated 5.7% and 3.6%, respectively (Table 4).

Comparison of severe cases among coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV)

In this meta-analysis, MERS-CoV was the most predominant causative agent of severe cases among infected pregnant women with a prevalence of 77% with 95% CI [23–97], followed by SARS-CoV rated 48% with 95% CI [32–65]. According to our findings, SARS-CoV-2 was the least causative agent of severe cases among the infected

---

### Table 3 Pooled prevalence of radiological findings and treatment of pregnant women with coronavirus infection in the present systematic review and meta–analysis

| Radiological finding and treatment of patients with CoV infection | Study (n) | Number of reports | Pregancies (n) | Pooled % (95%-CI) |
|---------------------------------------------------------------|----------|------------------|----------------|-------------------|
| **Radiological finding**                                      |          |                  |                |                   |
| Unilateral pneumonia                                          | 2        | 3                | 15             | 20% [4.4–48.6]    |
| Bilateral pneumonia                                            | 6        | 11               | 19             | 57.9% [33.5–80.1] |
| Ground-glass opacity                                           | 8        | 50               | 76             | 65.8% [54.2–76.4] |
| Multiple patchy infiltrate                                     | 5        | 5                | 22             | 22.7% [8.9–45.2]  |
| **Treatment**                                                  |          |                  |                |                   |
| Oseltamivir                                                    | 6        | 14               | 23             | 56.5% [35.1–64.3] |
| Remdesivir                                                     | 5        | 3                | 16             | 18.8% [13.8–29.1] |
| Lopinavir                                                      | 2        | 2                | 12             | 16.7% [13.1–41.1] |
| Ritonavir                                                      | 3        | 2                | 13             | 15.4% [10.1–31.7] |
| Ganciclovir                                                    | 7        | 2                | 10             | 20% [12.8–44.2]   |
| Ribavir                                                        | 11       | 15               | 23             | 65.2% [47.3–78.4] |
| Other antiviral therapy                                        | 11       | 89               | 128            | 69.5% [39.2–77.8] |
| Azithromycin                                                   | 4        | 7                | 20             | 35% [22.3–48.5]   |
| Other antibiotic therapy                                       | 13       | 102              | 157            | 64.9% [60.9–73.1] |
| Hydroxychloroquine                                             | 12       | 59               | 74             | 79.7% [70.1–89.3] |
| Hydrocortisone                                                 | 3        | 11               | 24             | 45.8% [37.2–59.6] |
| Mechanical ventilation                                        | 7        | 23               | 127            | 18.1% [12.26.8]   |
| Oxygen therapy                                                 | 9        | 89               | 113            | 78.8% [65.4–89.6] |

---
pregnant women, which rated 25% with 95% CI [7–59] (Fig. 2).

The effect of SARS-CoV-2, MERS-CoV, and SARS-CoV in pregnant women and their newborns

**SARS-CoV-2**

Out of 39 eligible articles, 25 studies [12, 26–49] reported information on infections caused by SARS-CoV-2 among a total of 1271 pregnancies. The prevalence of SARS-CoV-2 among preterm birth at <37 and 34 weeks of gestation was 14.3% and 8.9%, respectively, while 46.2% of pregnant women give birth at >37 weeks of gestation. Pre-eclampsia was reported among 5.7% of pregnant women with COVID-19. pPROM was reported in 8.9%, while the rate of fetal growth restriction was reported in 1.2%. In this study, miscarriage was rated 2.4%. ICU-admitted pregnant women were accounted for 28.5%, while the rate of maternal death was reported in 1.5%. The prevalence of cesarean delivery was 57% (Table 5). Fetal distress was reported among 25%, while the rate of neonatal asphyxia was 1.6%. The prevalence of Apgar score <7 at 5 min was 1.4%. The rate of newborns admitted to NICU was 11.6% in which perinatal death was reported among 2.9%. None of the studies reported transmission of SARS-CoV-2 from the mother to the fetus in utero during the follow-up period (Table 5).

**MERS-CoV**

Out of 35 eligible articles, seven studies [50–56] reported information on 12 pregnant women infected with MERS-CoV. The prevalence of preterm birth among pregnant women of <34 weeks of gestation was 33.3%, while 80% of pregnant women give birth at >37 weeks of gestation. Preeclampsia was observed among 5.7% of pregnant women infected with MERS-CoV. ICU-admitted pregnant women accounted for 33.3%, while the rate of maternal death was reported to be 40%. The prevalence of pregnant women given birth by cesarean was 66.7%, while 16.7% of pregnant women underwent normal delivery. Perinatal death was reported among 33.3% of the newborns, while none of the studies reported fetal distress, Apgar score <7 at 5 min, neonatal asphyxia, and

Table 4 Pooled proportions of the different maternal and postnatal outcomes and coexisting disorder identified in the present systematic review

| Pregnancy and perinatal postnatal outcome | Study (n) | Number of reports | Pregnancies or neonate (n) | Pooled % (95%–CI) |
|-------------------------------------------|-----------|-------------------|----------------------------|-------------------|
| **Pregnancy outcome**                     |           |                   |                            |                   |
| PTB < 34 week                             | 25        | 68                | 719                        | 9.5% [7.1–39.5]   |
| PTB < 37 week                             | 22        | 91                | 637                        | 14.3% [10.2–30.2] |
| > 37 week                                 | 25        | 330               | 709                        | 46.5% [41.2–56.3] |
| Pre-eclampsia                             | 9         | 10                | 169                        | 5.9% [3.6–11.7]   |
| pPROM                                     | 11        | 17                | 183                        | 9.3% [6.6–14.8]   |
| FGR                                       | 14        | 3                 | 108                        | 2.8% [1.8–8.9]    |
| Miscarriage                               | 4         | 9                 | 62                         | 14.5% [7.7–26.5]  |
| ICU admission                             | 29        | 66                | 211                        | 31.3% [27.2–55.5] |
| Maternal death                            | 11        | 15                | 557                        | 2.7% [1.4–14.6]   |
| Cesarean delivery                         | 32        | 440               | 772                        | 56.9% [48.2–78.9] |
| Normal delivery                           | 17        | 198               | 692                        | 28.6% [22.4–41.6] |
| **Prenatal outcome**                      |           |                   |                            |                   |
| Fetal distress                            | 17        | 18                | 68                         | 26.5% [17.5–39.5] |
| Apgar score < 7                           | 16        | 1                 | 81                         | 1.2% [0.0–7.7]    |
| Neonatal asphyxia                         | 11        | 1                 | 71                         | 1.4% [0.0–8.9]    |
| Admission to NICU                         | 8         | 9                 | 73                         | 11.3% [5.6–20.3]  |
| Perinatal death                           | 21        | 10                | 452                        | 2.2% [1.2–12.8]   |
| Vertical transmission                     | 39        | 0                 | 1316                       | 0.0% [0.0–1.0]    |
| **Coexisting disorders**                  |           |                   |                            |                   |
| Hypertension                              | 7         | 81                | 954                        | 8.5% [7.1–17.4]   |
| Gestational diabetes                      | 9         | 85                | 881                        | 9.6% [6.6–20.7]   |
| Cardiovascular disease                    | 2         | 27                | 470                        | 5.7% [3.0–12.1]   |
| Digestive disease                         | 3         | 4                 | 111                        | 3.6% [1.1–9.8]    |
| Asthma                                    | 4         | 44                | 794                        | 5.5% [2.3–36.4]   |

PTB preterm birth, pPROM preterm premature rupture of membranes, FGR fetal growth restriction, ICU intensive care unit, NICU neonatal intensive care unit
### SARS-CoV-2

| Study                  | Events | Total | Proportion | 95%-CI       |
|------------------------|--------|-------|------------|--------------|
| Chen [13] 2020         | 0      | 9     | 0.00       | [0.00; 0.34] |
| Zhu H [26] 2020        | 2      | 9     | 0.22       | [0.03; 0.60] |
| Penfield [27] 2020     | 5      | 11    | 0.45       | [0.17; 0.77] |
| Liu [28] 2020          | 3      | 3     | 1.00       | [0.29; 1.00] |
| Yan J [29] 2020        | 8      | 65    | 0.12       | [0.05; 0.23] |
| Zhang 30 [30] 2020     | 1      | 16    | 0.06       | [0.00; 0.30] |
| Pierce [31] 2020       | 64     | 64    | 1.00       | [0.94; 1.00] |
| Chen S [32] 2020       | 0      | 6     | 0.00       | [0.00; 0.52] |
| Dong [33] 2020         | 1      | 1     | 1.00       | [0.00; 1.00] |
| Li [36] 2020           | 0      | 1     | 0.00       | [0.00; 0.98] |
| Cui Y [38] 2020        | 1      | 1     | 1.00       | [0.00; 1.00] |
| Yu [39] 2020           | 0      | 7     | 0.00       | [0.00; 0.41] |
| Breslin [41] 2020      | 6      | 43    | 0.14       | [0.05; 0.28] |
| Liu Y [42] 2020        | 2      | 13    | 0.15       | [0.02; 0.45] |
| Knight [45] 2020       | 40     | 427   | 0.09       | [0.07; 0.13] |
| Andrikopoulou (48) 2020| 34     | 158   | 0.22       | [0.15; 0.29] |

**Random effects model**

| 833 | 0.25 [0.07; 0.59] |

Heterogeneity: $I^2 = 97\%$, $\tau^2 = 7.1692$, $p = 0.88$

### MERS-CoV

| Study                  | Events | Total | Proportion | 95%-CI       |
|------------------------|--------|-------|------------|--------------|
| Assiri [46]            | 5      | 5     | 1.00       | [0.48; 1.00] |
| Alfaraj [47]           | 1      | 2     | 0.50       | [0.01; 0.99] |
| Jeong [48]             | 0      | 1     | 0.00       | [0.00; 0.98] |
| Park [49]              | 1      | 1     | 1.00       | [0.03; 1.00] |
| Malik [50]             | 1      | 1     | 1.00       | [0.03; 1.00] |
| Payne [51]             | 0      | 1     | 0.00       | [0.00; 0.98] |
| Alserehi [52]          | 1      | 1     | 1.00       | [0.03; 1.00] |

**Random effects model**

| 12 | 0.77 [0.23; 0.97] |

Heterogeneity: $I^2 = 58\%$, $\tau^2 = 3.3685$, $p = 1.00$

### SARS-CoV

| Study                  | Events | Total | Proportion | 95%-CI       |
|------------------------|--------|-------|------------|--------------|
| Robertson [53]         | 1      | 1     | 1.00       | [0.03; 1.00] |
| Stockman [54]          | 0      | 1     | 0.00       | [0.00; 0.98] |
| Lam [55]               | 6      | 10    | 0.60       | [0.26; 0.88] |
| Wong [56]              | 6      | 12    | 0.50       | [0.21; 0.79] |
| Schneider [57]         | 0      | 1     | 0.00       | [0.00; 0.98] |
| Ng [58]                | 3      | 7     | 0.43       | [0.10; 0.82] |
| Rudin [59]             | 0      | 1     | 0.00       | [0.00; 0.98] |

**Random effects model**

| 33 | 0.48 [0.32; 0.65] |

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 1.00$

---

**Fig. 2** Pooled proportions of severe cases in the overall population of pregnancies infected with coronavirus infection.
Table 5 Pooled proportions of the different pregnancy and perinatal outcomes identified in the present systematic review

| Pregnancy outcome | SARS-CoV-2 | MERS-CoV | SARS-CoV |
|-------------------|------------|----------|----------|
|                   | Study (n)  | Reports (n) | Pregnancies or neonate (n) | Pooled % (95%-CI) | Study (n) | Reports (n) | Pregnancies or neonate (n) | Pooled % (95%-CI) | Study (n) | Reports (n) | Pregnancies or neonate (n) | Pooled % (95%-CI) |
| PTB < 34 week     | 11         | 61        | 682      | 8.9% [6.1–19.3] | 7          | 4          | 12        | 33.3% [14.2–38.9] | 7          | 3          | 25        | 12% [3.6–31.5] |
| PTB < 37 week     | 9          | 86        | 602      | 14.3% [9.2–33.2] | 7          | 0          | 12        | 0.0% [0.0–7.4]  | 6          | 5          | 23        | 21.7% [7.4–44.6] |
| > 37 week         | 13         | 317       | 686      | 46.2% [41.5–58.9] | 5          | 8          | 10        | 80% [44.2–97.8] | 7          | 5          | 13        | 38.5% [00–68.4] |
| Preeclampsia      | 5          | 9         | 159      | 5.7% [3.3–10.1]  | 2          | 1          | 8         | 12.5% [0.0–53.6] | 2          | 0          | 2         | 0% [0.0–84.7]  |
| pPROM             | 7          | 16        | 179      | 8.9% [5.5–14.6]  | 2          | 0          | 2         | 0.0% [0.0–84.2] | 2          | 1          | 8         | 12.5% [00–53.8] |
| FGR               | 4          | 1         | 86       | 1.2% [0.0–6.3]   | 4          | 0          | 6         | 0.0% [0.0–46.5] | 6          | 2          | 16        | 12.5% [2.2–38.6] |
| Miscarriage       | 2          | 1         | 41       | 2.4% [0.0–13.5]  | –          | –          | –         | –                    | 2          | 8          | 21        | 38.1% [18.7–62.5] |
| ICU admission     | 25         | 53        | 186      | 28.5% [23.1–54.4] | 2          | 1          | 3         | 33.3% [1.2–91.3] | 2          | 12         | 22        | 54.5% [32.1–76.8] |
| Maternal death    | 4          | 8         | 523      | 1.5% [1.2–9.6]   | 4          | 4          | 10        | 40% [1.25–74.3] | 3          | 3          | 24        | 12.5% [3.3–32.9] |
| Cesarean delivery | 19         | 426       | 747      | 57.0% [48.9–78.6] | 6          | 6          | 9         | 66.7% [50.2–93.5] | 6          | 8          | 16        | 50% [25.6–75.9] |
| Normal delivery   | 11         | 192       | 662      | 29.0% [21.4–33.5] | 2          | 2          | 12        | 16.7% [2.4–48.6] | 4          | 4          | 18        | 22.2% [6.6–48.7] |
| Perinatal outcome | Fetal distress | 7          | 14        | 56       | 25% [14.4–39.6] | 5          | 0          | 0         | 0.0% [0.0–52.3] | 5          | 4          | 12        | 33.3% [10.1–65.2] |
|                   | Apgar score < 7 | 7          | 1         | 72       | 1.4% [0.0–7.8]  | 4          | 0          | 4         | 0.0% [0.0–60.1] | 5          | 0          | 5         | 0% [0.0–52.3]  |
|                   | Neonatal asphyxia | 4          | 1         | 64       | 1.6% [0.0–8.9]  | 3          | 0          | 3         | 0.0% [0.0–71.4] | 4          | 0          | 4         | 0.0% [0.0–60.8] |
|                   | Admission to NICU | 4          | 8         | 69       | 11.6% [5.4–22.6] | 3          | 1          | 3         | 33.3% [1.3–845] | 1          | 0          | 1         | 0% [0.0–98.5]  |
|                   | Perinatal death  | 8          | 5         | 430      | 1.2% [1.0–8.7]  | 7          | 4          | 12        | 33.3% [10.6–653] | 6          | 1          | 10        | 10% [0.0–45.3] |
|                   | Vertical transmission | 25         | 0         | 1271     | 0.0% [0.0–15.5] | 7          | 0          | 12        | 0.0% [0.0–26.5] | 7          | 0          | 7         | 0% [0.0–41.6]  |

PTB preterm birth, pPROM preterm premature rupture of membranes, FGR fetal growth restriction, ICU intensive care unit, NICU neonatal intensive care unit
admission to the neonatal intensive care unit. None of the studies reported transmission of MERS-CoV from the mother to the fetus in utero during the follow-up period (Table 5).

**SARS-CoV**
Out of 35 eligible articles, seven studies [57–63] reported information on 33 pregnant women infected with SARS-CoV. The prevalence of SARS-CoV among preterm birth < 37 and 34 weeks of gestation was 21.7% and 12%, respectively, while 38.5% of pregnant women give birth at > 37 weeks of gestation. pPROM was reported in 12.5%, while the rate of fetal growth restriction was reported in 12.5%. Miscarriage was reported among 38.1% of pregnant women. ICU admitted pregnant women were accounted for 54.5%, while the rate of maternal death was reported in 12.5%. The prevalence of pregnant women giving birth by cesarean was 50%, while 22.2% of pregnant women underwent normal delivery. The prevalence of fetal distress and perinatal death was 33.3% and 10%, respectively, while none of the studies reported apgar score < 7 at 5 min, neonatal asphyxia and admission to the neonatal intensive care unit. None of the studies reported transmission of SARS-CoV from the mother to the fetus in utero during the follow-up period (Table 5).

**Heterogeneity and risk of bias**
Subgroup analysis was conducted to justify the cause of heterogeneity. Subgroup analysis of the included studies showed that the possible cause of heterogeneity was a sample size difference, especially in SARS-CoV-2 ($I^2 = 94\%$). The funnel plots suggest a publication bias for some of the study of the parameters ($P < 0.02$).

**Discussion**

**Summary of findings**
We conducted a systematic review and meta-analysis to provide an overview of the effect of CoV (SARS-CoV-2, MERS-CoV, and SARS-CoV) infection on maternal and perinatal, and the possibility of vertical transmission of the virus from pregnant women to the fetus. The rapidly spreading nature of COVID-19 and previous CoV infections could have a significant effect on human health. Thus, attention should be given to pregnant women, and they should be included in preparedness and response plans. In previous outbreaks, clinicians did not volunteer to treat or vaccinate pregnant women because of concerns for fetal safety [64]. The pregnant state, with alterations in hormone levels and decreased lung volumes due to a gravid uterus and slightly immunocompromised state may predispose patients to a more rapidly deteriorating clinical course and face a greater risk of harm if they get respiratory infections.

In the current study, the predominant signs and symptoms of hospitalized pregnant women suffering from COVID-19 and other coronavirus infections were viral pneumonia, fever, cough, fatigue, and myalgia. The Centre for disease control listed these symptoms to be the leading clinical feature of patients infected with COVID-19 and other coronaviruses [65]. The high fever after delivery may have resulted from immunity reduction due to fatigue and blood loss in childbirth, anatomy of female genitalia, sweating during puerperium, and postpartum lactation. Once postpartum fever occurred, obstetricians and gynecologists should follow and perform a differential diagnosis to exclude breast swelling, mastitis, urinary tract infections, common colds, and reproductive tract infections must be focused on. Gastrointestinal symptoms like diarrhea and abdominal pain were also observed in pregnant women with COVID-19 and other coronavirus infections. Gestational diabetes and hypertension were the most common coexisting disorders with a prevalence of 9.6% and 8.5%. More than half of the pregnant women infected with coronaviruses were treated by antiviral and antibiotic therapy.

In our study, the most frequently reported laboratory findings was lymphocytopenia (66.1%), followed by elevated C-reactive protein marker (56.6%), leukopenia (48.3%) and elevated lactate dehydrogenase (34.8%). This is similar to previous studies reporting on COVID-19 and other CoV infections [66–69]. Laboratory findings like leukopenia and lymphocytopenia were helpful to distinguish viral infections from common bacterial infections [70]. The most common computed tomography imaging features in pregnant women with COVID-19 and non-COVID-19 pneumonia were ground-glass opacity and bilateral pneumonia with a prevalence of 57.9% and 65.8%, respectively. The pathological basis of these changes could be due to inflammatory cell infiltration and interstitial thickening, cell exudation, and hyaline membrane formation. The most common treatment options used were hydroxychloroquine (79.7%), ribavirin (65.2%), oseltamivir (56.5%) and azithromycin (35%) to treat common bacterial pathogens when secondary infections occurred and treat viral pathogens. Among CoV-infected pregnant women, oxygen therapy was 78.8%.

Based on the findings of the present study, higher prevalence of COVID-19 and other CoV was reported among preterm birth < 37 weeks of gestation. According to some studies report, infection with COVID-19 during pregnancy can cause complications for both the mother and the fetus [59, 71]. This includes preeclampsia, preterm premature rupture of membranes, fetal growth restriction, and miscarriage. Large numbers of CoV-infected pregnant women with severe cases were admitted to the intensive care unit which even
resulted in the death of some mothers. Cesarean deliveries occurred among three-fourths of pregnant women infected with CoV. Regarding the perinatal outcome, fetal distress and neonatal asphyxia were the most commonly reported abnormalities in newborn. The rate of newborns admitted to the neonatal intensive care unit was around 11.3% while 2.2% of them died. MERS-CoV was the predominant causative agent of severe cases in infected pregnant women.

There is much controversy relating to the possibility of in utero transmission of SARS-CoV-2, MERS-CoV, and SARS-CoV. Multiple samples were obtained at the time of labor and delivery to test for the presence of coronavirus by qRT-PCR, including amniotic fluid aspirated from the vagina during labor, cord blood, and segments of the umbilical cord, fetal membranes, and placenta, neonatal nasopharyngeal and throat swabs, gastric aspirate and meconium samples tested negative for the coronaviruses, suggesting there was no evidence of vertical transmission in women who developed COVID-19 and non-COVID-19 coronavirus pneumonia in late pregnancy [12, 63, 72]. Studies conducted in London [73] reported a neonate born to a pregnant woman with COVID-19 that tested positive for SARS-CoV-2 in the pharyngeal swab sample 36 h after birth, it was subsequently confirmed that qRT-PCR testing of the placenta and cord blood was negative for SARS-CoV-2, it is believed that the mother or a family member transmitted the infection to the infant through close contact after delivery, not in utero through placenta [39, 74].

In the current study, the systematic testing procedures for coronavirus infection, including chest radiograph and serial RT-PCR assays with multiple clinical samples did not demonstrate the presence of SARS-CoV-2, MERS-CoV and SARS-CoV in the newborn. CoV antibody tests were performed with mother and newborn sera. In some mothers’ sera immunoglobulin G was detected by using serological tests. However, CoV antibodies for IgG, IgM, and IgA were detected in none of the newborn's blood samples [55, 75]. Therefore, there is no evidence of intrauterine transmission of SARS-CoV-2 and other CoV from mother to newborn infants. This may be due to a very low expression of angiotensin-converting enzyme 2 (ACE2) in early maternal–fetal interface cells as suggested by different experts.

Limitations of the study
Only English articles or reports were considered for this review. The small number of cases in some of the included studies, the study design, and the lack of standardized criteria were the major limitations of this systematic review. Additionally, there is a possibility that some patients were included in more than 1 report, although all authors independently reviewed all the included studies, carefully focusing on the different institutions reporting outcomes. We included case reports and case series, thus facing a higher risk of publication bias, which could affect the estimated outcome. Furthermore, lack of denominator in case series used in this review is the other major factor that affects the estimated outcome. Moreover, when focusing on the outcomes of COVID-19 infection, and particularly perinatal outcomes, reported data are intuitively limited to a very short-term follow-up period and thus infections that occurred proximate to the delivery. This has the potential to overestimate the magnitude of risks such as PTB and underestimate more longitudinal risks such as FGR. In some of the studies, we did not find standardized criteria and timing of delivery of pregnancies affected by CoV infection.

Conclusion
In general, based on the published data collected, fever, cough, and myalgia were the most common clinical features, while the predominant abnormal laboratory findings reported were lymphocytopenia and C-reactive protein. Bilateral pneumonia and ground-glass opacity were the most common radiological abnormal findings. Oxygen therapy was the most common treatment option used while bacterial coinfection was treated by antibiotics therapy, and viral pathogen was treated by antiviral therapy. Among the coronavirus species, MERS-CoV was the leading cause of severe cases in infected pregnant women. Pregnant women infected with coronaviruses are at increased risk of adverse obstetrical outcomes, compared with the general population. The infection outcome was mainly associated with a relatively higher rate of cesarean delivery, preterm birth, intensive care unit admission, preeclampsia, miscarriage, fetal distress, and perinatal death. None of the studies reported transmission of CoV from the mother to the fetus in utero. This may be due to a very low expression of angiotensin-converting enzyme 2 (ACE2) in early maternal–fetal interface cells as suggested by different experts.

Abbreviations
CoV: Coronavirus; FGR: Fetal growth restriction; ICU: Intensive care unit; JBI: Joanna Briggs Institute; MERS-CoV: Middle East respiratory syndrome coronavirus; NICU: Neonatal intensive care unit; pPROM: Preterm prelabor rupture of...
membranes; PTB: Preterm birth; RT-PCR: Real-time polymerase chain reaction; qRT-PCR: Quantitative real-time polymerase chain reaction; SARS-CoV: Severe acute respiratory syndrome coronavirus.

Acknowledgements

The authors would like to acknowledge authors of primary study and Dilla University, College of health science and medicine and department of medical laboratory science.

Authors’ contributions

KD is the first and corresponding author. KD and EA conceived and designed the study. KD and EG acquired the data. KD and EA analyzed the data and interpreted the results. KD drafted the initial and final manuscripts. KD, EA, and EG performed critical revisions of the manuscript. All authors read and approved the final manuscript.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

All data relevant to the study are included in the article.

Ethics approval and consent to participate

Ethical approval was not required because the analysis under consideration is from data already publicly available in published studies.

Consent for publication

Not required.

Competing interests

The authors declare that they have no competing interests.

Received: 3 June 2020   Accepted: 19 August 2020

Published online: 04 September 2020

References

1. Poon LC, Yang H, Lee JC, Copel JA, Leung TY, Zhang Y, et al. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol. 2020. https://doi.org/10.1002/uog.22013.

2. Lau SK, Woo PC, Li KS, Huang Y, Toi H-W, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci. 2005;102(39):14040–5.

3. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.

4. Organization WH. WHO director–general’s opening remarks at the media briefing on covid-19 11 march 2020. 2020, 2020.

5. Perlman S. Another decade, another coronavirus. Mass Medical Soc; 2020.

6. Hui DS, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin. 2019;33(4):869–89.

7. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy: Am J Reprod Immunol. 2015;73(3):199–213.

8. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194.

9. Maxwell C, McGeer A, Tai KFY, Sermer M. No. 225-Management guidelines for obstetric patients and neonates born to mothers with suspected or probable Severe Acute Respiratory Syndrome (SARS). J Obstet Gynaecol Canada. 2017;39(3):e130–e17.

10. Rao Q. What are the risks of COVID-19 infection in pregnant women? Lancet. 2020;395(10226):760–2.

11. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020;144:799–805.

12. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intratracheal vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–15.

13. Schwartz DA. Maternal and infant death and the nSARS-ZEBOV virus through three recent ebola virus Epidemics-West Africa, DRC Equateur and DRC Kivu: 4 years of excluding pregnant and lactating women and their infants from immunization. Curr Trop Med Rep. 2019;6(4):213–22.

14. Schwartz DA, Anoko JN, Abramowitza SA. Pregnant in the time of ebola: women and their children in the 2013–2015 West African Epidemic. Berlin: Springer; 2019.

15. Arkesey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000060.

17. Moher D, Pham B, Lawson M, Klassen T. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7(41):1–90.

18. Armstrong R, Waters E, Jackson N. Systematic reviews of health promotion and public health interventions. Melbourne: University of Melbourne; 2007.

19. Cheng Z, Liu Y, Cao Q, Qin L, Pan Z, Yan F, et al. Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. Am J Roentgenol. 2019;2020:1–6.

20. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8(1):79.

21. Nyaga VN, Arbyn M, Aerts M. Metaprop: a stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39.

22. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693–708.

23. Cochran WG. The comparison of percentages in matched samples. Biom. 1950;37(3/4):256–66.

24. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7096):629–34.

25. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51.

26. Penfold CA, Brubaker SG, Limaye MA, Lighter J, Ratner AJ, Thomas KM, et al. Detection of SARS-COV-2 in placental and fetal membrane samples. Am J Obstet Gynecol MFM. 2020. https://doi.org/10.1016/j.ajogm.2020.100133.

27. Liu W, Wang Q, Zhang Q, Chen L, Chen J, Zhang B, et al. Coronavirus disease 2019 (COVID-19) during pregnancy: a case series; 2020.

28. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.04.014.

29. Zhang LuJ, Min W. Analysis of pregnancy outcomes of pregnant women during the epidemic of new coronavirus pneumonia in Hubei (J/OL). Chin J Obstet Gynecol. 2020;55:166–71.

30. Pierce-Williams RA, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.100134.

31. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. J Med Virol. 2020;92:1556–61.

32. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA. 2020;323:1846–8.

33. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, et al. Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa226.

34. Yang P, Wang X, Liu P, Wei C, He B, Zheng J, et al. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. J Clin Virol. 2020;127:104356.

35. Li Y, Zhao R, Zheng S, Chen X, Wang J, Sheng X, et al. Early release-lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, China. 2020.
36. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X, et al. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa200.

37. Cui Y, Tian M, Huang D, Wang X, Huang Y, Fan L, et al. A 55-day-old female infant infected with 2019 novel coronavirus disease: presenting with pneumonia, liver injury, and heart damage. J Infect Dis. 2020;221(1):1775–81.

38. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020;20:559–64.

39. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020;174:722–5.

40. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.100118.

41. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.02.028.

42. Liu D, Li L, Wu X, Zheng D, Wang J, Yang L, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. Am J Roentgenol. 2020;215:127–32.

43. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children. J Infect. 2020;80:e7–13.

44. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Front Med. 2020. https://doi.org/10.1007/s11686-020-0772-y.

45. Knight M, Bunch K, Vosden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS). medRxiv; 2020.

46. Løkkken EM, Walker CL, Delaney S, Karvits K, Erickson A, et al. Clinical characteristics of 46 pregnant women with a SARS-CoV-2 infection in Washington State. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.05.031.

47. Lumberas-Marquez M, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. Maternal mortality from COVID-19 in Mexico. Int J Gynaecol Obstet. 2020;200(2):266–7.

48. Andrakopoulos M, Maddern N, Wen T, Aubey JJ, Aziz A, Baptiste CD, et al. Symptoms and critical illness among obstetric patients with coronavirus disease 2019 (COVID-19) infection. Obstet Gynecol. 2020;136:291–9.

49. Assiri A, Abedi GR, Al Masri M, Bin Saeed A, Gerber SI, Watson JT. Middle East respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis. 2004;10(2):345.

50. Stockman LJ, Lowther SA, Coy K, Saw J, Parashar UD. SARS during pregnancy, United States. 2004.

51. Lamnt CM, Wong SF, Leung TN, Chow KM, Yu WC, Wong TY, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG Int J Obstet Gynaecol. 2004;111(8):771–4.

52. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191(1):292–7.

53. Schneider E, Duncan D, Reiken M, Perry R, Messick J, Sheedy C, et al. SARS in pregnancy: this case study explores the first documented infection in the US. AWIONN lifelines. 2004;8(2):122–8.

54. Ng W, Wong S, Lam A, Mak Y, Yao H, Lee K, et al. The placenta of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006;38(3):210–8.

55. Yudin MH, Steele DM, Sgro MD, Read SE, Kopplin P, Gough KA. Severe acute respiratory syndrome in pregnancy. Obstet Gynecol. 2005;105(3):124–7.

56. Haddad LB, Jamieson DJ, Rasmussen SA. Pregnant women and the Ebola crisis. N Engl J Med. 2018;379(26):2492–3.

57. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV) Radiology. 2020;295(1):202–7.

58. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10233):507–13.

59. Cai J, Xu J, Lin D, Xu L, Qu Z, Zhang Y, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa198.

60. Assir A, McGeer A, Perl TM, Price CS, Al Rabeaah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus N Engl J Med. 2013;369(5):407–16.

61. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–24.

62. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia: je he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis. 2020;43:E005.

63. Liu D, Li L, Wu X, Zheng D, Wang J, Liang B. Pregnancy and perinatal outcomes of women with COVID-19 Pneumonia: a preliminary analysis. Available at SSRN.

64. Lei D, Wang C, Li C, Fang C, Yang W, Cheng B, et al. Clinical characteristics of COVID-19 in pregnancy: analysis of nine cases. Chin J Perinat Med. 2020;23(03):225–31.

65. Murphy S. Newborn baby tests positive for coronavirus in London. The Guardian. 2020;2020:43.E005.

66. Cai J, Xu J, Lin D, Xu L, Qu Z, Zhang Y, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa198.

67. Rush J, Lee JY, Baek JY, Seok H, Park GE, Lee JY, et al. Serologic evaluation of SARS-CoV-2 antibodies in the 19 patients with COVID-19 pneumonia: a retrospective study comparing pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG Int J Obstet Gynaecol. 2020. https://doi.org/10.1111/bjo.15712.

68. Kuo J, Pau L, Duan T, Lin L-P. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal–Fetal interface. Reprod Dev Med. 2020;43:E005.

69. Liu D, Li L, Wu X, Zheng D, Wang J, Liang B. Pregnancy and perinatal outcomes of women with COVID-19 Pneumonia: a preliminary analysis. Available at SSRN.

70. Schneider E, Duncan D, Reiken M, Perry R, Messick J, Sheedy C, et al. SARS in pregnancy: this case study explores the first documented infection in the US. AWIONN lifelines. 2004;8(2):122–8.

71. Ng W, Wong S, Lam A, Mak Y, Yao H, Lee K, et al. The placenta of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006;38(3):210–8.

72. Yudin MH, Steele DM, Sgro MD, Read SE, Kopplin P, Gough KA. Severe acute respiratory syndrome in pregnancy. Obstet Gynecol. 2005;105(3):124–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.